Scarica l'app Stockscreener
11.42
5.46%
-0.66
Dopo l'orario di chiusura:
11.46
0.04
+0.35%
Precedente Chiudi:
$12.08
Aprire:
$12
Volume 24 ore:
2.12M
Relative Volume:
1.33
Capitalizzazione di mercato:
$1.25B
Reddito:
$-249.00K
Utile/perdita netta:
$-187.60M
Rapporto P/E:
-4.568
EPS:
-2.5
Flusso di cassa netto:
$-201.88M
1 W Prestazione:
-7.38%
1M Prestazione:
-16.95%
6M Prestazione:
+73.82%
1 anno Prestazione:
+192.07%
Intervallo 1D:
$11.06
$12.11
Intervallo di 1 settimana:
$11.06
$12.57
Portata 52W:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-683-0917
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Confronta AMLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
11.42 | 1.33B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data - Quiver Quantitative
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 7.2%Time to Sell? - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Guidance Update: What margin trends mean for Amylyx Pharmaceuticals Inc stockPortfolio Return Summary & Daily Oversold Bounce Ideas - moha.gov.vn
Hedge Fund and Insider Trading News: Ken Griffin, Ray Dalio, Warren Buffett, Toms Capital, Ken Fisher, Pershing Square, Amylyx Pharmaceuticals Inc (AMLX), NVIDIA Corp (NVDA), and More - Insider Monkey
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase - Quiver Quantitative
Amylyx announces proposed public offering of common stock - MSN
How Investors Are Reacting To Amylyx Pharmaceuticals (AMLX) Early AMX0114 Safety Data And Insider Buying - Sahm
Amylyx Pharma director Firestone buys $100k in AMLX stock By Investing.com - Investing.com UK
Amylyx Pharma director Firestone buys $100k in AMLX stock - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Acquires $100,845.00 in Stock - MarketBeat
Amylyx Pharmaceuticals Director Karen Firestone Acquires 8,100 Shares - TradingView — Track All Markets
Will Amylyx Pharmaceuticals Inc. stock deliver long term returnsEvening Star Patterns & Free Rapid Return Acceleration - Bollywood Helpline
How Amylyx Pharmaceuticals Inc. stock trades before earningsLayoff News & Verified Momentum Watchlists - Улправда
Will Amylyx Pharmaceuticals Inc. stock recover faster than peers2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Will Amylyx Pharmaceuticals Inc. stock return to pre crisis levelsBull Run & Expert Approved Momentum Trade Ideas - Улправда
Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotation2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Is Amylyx Pharmaceuticals Inc. stock recession proofTrade Risk Report & High Conviction Buy Zone Alerts - DonanımHaber
What margin trends mean for Amylyx Pharmaceuticals Inc. stockMarket Activity Summary & High Conviction Buy Zone Picks - DonanımHaber
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuationEarnings Summary Report & Weekly Sector Rotation Insights - ulpravda.ru
AMLX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class ActionAMLX - TMX Newsfile
Amylyx Pharmaceuticals Earnings Notes - Trefis
TFG Asset Management GP Ltd Makes New $1.40 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
683 Capital Management LLC Has $13.85 Million Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
ALS medication AMX0114 shows safety, moves to 2nd trial group - ALS News Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 12.96% to 20.74 - MSN
Amylyx pins its next hopes on a niche drug in the obesity space - Pharma Voice
Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge? - Sahm
Amylyx presents safety outcomes of AMX0114 in LUMINA study - MSN
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? - Nasdaq
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Mizuho Securities - The Globe and Mail
Rare Disease Leaders Call for Regulatory Consistency After Chaotic Year - BioSpace
Amylyx’s ALS drug AMX0114 shows positive early safety data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Positive Buy Rating for Amylyx Pharmaceuticals Based on Promising Phase I LUMINA Study Results and Strategic Advancements - TipRanks
Presentation at MNDA: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial (dae63b) - marketscreener.com
Amylyx’s ALS drug AMX0114 shows positive early safety data - Investing.com India
Amylyx Pharmaceuticals announces new safety and tolerability cohort 1 data of amx0114 - marketscreener.com
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Increased by Saturn V Capital Management LP - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Lifted by Alpha Wave Global LP - MarketBeat
Can Amylyx Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Camille Bedrosian Sells 6,580 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Geode Capital Management LLC Acquires 886,252 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Top Executive Makes Significant Stock Sale at Amylyx Pharmaceuticals - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 04 - marketscreener.com
Amylyx Pharmaceuticals CMO Sells Shares to Cover Tax Obligations - TradingView
Officer Bedrosian Surrenders 6,580 Of Amylyx Pharmaceuticals Inc [AMLX] - TradingView
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? - Yahoo Finance
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.19%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):